Caplin Point Laboratories is a fast growing, fully integrated Pharmaceutical company with a dominant presence in Latin America, Francophone Africa and a growing presence in the Regulated markets such as USA and EU. The company was established in 1990 to manufacture a range of ointments, creams and other external applications. The company was listed in 1994 following its Initial Public Offering (IPO), the proceeds of which were deployed in setting up a manufacturing facility at Pondicherry. Thereafter, the company expanded its product range and increased its production capacity. The company has own state of the art manufacturing facilities that cater to a complete range of finished dosage forms.

The Company focused on the emerging markets of Latin America, Caribbean, Francophone and Southern Africa and is one of the leading suppliers of Pharmaceuticals in these regions, with various product licenses across the globe. The company thrives on a unique business model of owning distribution networks, catering predominantly to the Bottom of the Pyramid, in the areas of its presence. Caplin Point maintains deep focus on innovative technologies and products, with a sizeable part of its annual earnings invested into Research & Development of safe and effective products across varied dosage forms.

Business area of the company

Caplin Point Laboratories is engaged in manufacture of pharmaceuticals formulations. It is a fast-growing Indian pharmaceutical company with global reach, having a 100% export-oriented business. The company supplies a complete range of finished dosage forms. The company operates on a unique business model which predominantly caters to emerging markets of Latin America and Africa and a growing presence in regulated markets like the USA, Canada, Australia etc. 

Products

Regulated Markets

• Liquid & Lyophilized Vials
• Pre-Filled Syringes
• 3-pc Ophthalmic Droppers
• Pre-Mix Bags

Emerging Markets

• Tablets
• Dry syrups - Bottles
• Softgels
• Capsules
• Suppositories
• Liquid syrups - Bottles
• liquid injectables in ampoules & vials
• Lyophilized vials
• Prefilled syringes (PFS)
• Emulsion injection in ampoules & vials
• Topicals
• Sachets (Liquids & Powders)

Awards and recognitions

• 2014: Forbes Asia Best under a Billion Award - 2014.
• 2015: Forbes Asia Best under a Billion Award - 2015.
• 2016: Forbes Asia Best under a Billion Award - 2016.
• 2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
• 2017: Financial express CFO Awards 2017 (Second Rank).
• 2017: IPF’s industrial Excellance Award.
• 2018: The Economic Times - Family Business of the year Award.
• 2018: Pharmexcil Outstanding Exports Award 2018.
• 2018: The Economic Times Award for Excellence in Business Performance.
• 2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.
  
• 2022: Hindustan Chamber of Commerce - Business Excellence Award - 2022.
• 2023: Life Time Achievement Award - Business Puthiya Thalaimurai Tamilan Awards - 2023.
• 2023: Forbes Asia Best Under Billion Award - 2023.
• 2024: Forbes Asia Best Under a Billion award for 2024.
• 2024: 2024 Hurun India - Pioneer in advancing pharmaceutical excellence.

Milestones

• 1990: Incorporation.
• 1994: Listed on Stock Exchange.
• 2001: Entered Angola with unique Stock & Sale model.
• 2005: Started outsourcing from China.
• 2006: Entered the Caribbean and Latin America.
• 2014: Work on Regulated Markets 
• 2014: Injectable unit starts.
• 2017: Liquid injectable facility gets EU & USFDA Approval.
• 2018: Started first commercial shipments to US.
• 2019: Fidelity investment into Caplin Steriles.
• 2021: Commences Capex expansion in multiple projects equaling Rs 600 crore CRO wing
• 2021: Amaris Clinical gets USFDA approval.
• 2022: Company acquires API plant in Vizag, as part of backward integration move. 
• 2022: Amaris Clinical gets ISP Chile approval.
• 2023: Incorporates Caplin Steriles USA Inc. (CSU) for launching own label in US.
• 2024: Oncology facility started production at SIDCO Kakkalur, Chennai.
• 2025: CSU commencement of operations.